StocksFundsScreenerSectorsWatchlists
CRMD

CRMD - CorMedix Inc Stock Price, Fair Value and News

4.23USD+0.07 (+1.68%)Delayed as of 28 Mar 2024, 10:56 am ET

Market Summary

CRMD
USD4.23+0.07
Delayedas of 28 Mar 2024, 10:56 am
1.68%

CRMD Alerts

  • 1 major insider buys recently.

CRMD Stock Price

View Fullscreen

CRMD RSI Chart

CRMD Valuation

Market Cap

228.7M

Price/Earnings (Trailing)

-4.94

Price/Sales (Trailing)

576.77

EV/EBITDA

-4.66

Price/Free Cashflow

-5.9

CRMD Price/Sales (Trailing)

CRMD Profitability

Operating Margin

100.00%

EBT Margin

-9522.27%

Return on Equity

-66.01%

Return on Assets

-56.42%

Free Cashflow Yield

-16.94%

CRMD Fundamentals

CRMD Revenue

Revenue (TTM)

326.0K

CRMD Earnings

Earnings (TTM)

-46.3M

Earnings Growth (Yr)

-79.25%

Earnings Growth (Qtr)

-51.01%

Breaking Down CRMD Revenue

52 Week Range

3.426.09
(Low)(High)

Last 7 days

2.9%

Last 30 days

18.4%

Last 90 days

4.5%

Trailing 12 Months

1.9%

How does CRMD drawdown profile look like?

CRMD Financial Health

Current Ratio

6.97

CRMD Investor Care

Shares Dilution (1Y)

32.77%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
202292.3K170.2K248.1K326.0K
2021253.4K245.2K190.3K14.4K
2020193.6K174.8K208.3K239.2K
2019570.3K598.0K285.0K283.3K
2018313.0K184.4K495.8K429.8K
2017222.2K341.9K358.5K329.3K
2016220.3K116.8K125.3K224.1K
2015208.3K288.6K272.1K210.1K
2014000189.3K
20130000

Tracking the Latest Insider Buys and Sells of CorMedix Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 13, 2024
todisco joseph
bought
50,718
3.74
13,561
chief executive officer
Jan 12, 2024
masson-hurlburt elizabeth
acquired
-
-
50,000
evp, head of clinical ops.
Jan 12, 2024
mistry erin
sold (taxes)
-15,229
3.47
-4,389
chief commercial officer
Jan 12, 2024
todisco joseph
acquired
-
-
133,333
chief executive officer
Jan 12, 2024
mistry erin
acquired
-
-
50,000
chief commercial officer
Jan 12, 2024
todisco joseph
sold (taxes)
-47,820
3.47
-13,781
chief executive officer
Jan 12, 2024
david matthew t
sold (taxes)
-18,099
3.47
-5,216
chief financial officer
Jan 12, 2024
masson-hurlburt elizabeth
sold (taxes)
-15,972
3.47
-4,603
evp, head of clinical ops.
Jan 12, 2024
david matthew t
acquired
-
-
50,000
chief financial officer
Dec 15, 2023
dunton alan w
bought
9,900
3.3
3,000
-

1–10 of 50

Which funds bought or sold CRMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
68.00
68.00
-%
Mar 11, 2024
VANGUARD GROUP INC
added
6.59
815,491
10,623,300
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
72.63
119,801
278,616
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
4.98
6,438
102,719
-%
Feb 26, 2024
Virtu Financial LLC
new
-
103,000
103,000
0.01%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
3.00
188
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
1,000
46,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
93,000
93,000
0.01%
Feb 15, 2024
Legal & General Group Plc
added
10.88
2,612
23,222
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
399
399
-%

1–10 of 45

Are Funds Buying or Selling CRMD?

Are funds buying CRMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRMD
No. of Funds

Unveiling CorMedix Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
nomura holdings inc
5.4%
2,946,531
SC 13G/A
Feb 13, 2024
vanguard group inc
5.15%
2,825,335
SC 13G
Jan 29, 2024
blackrock inc.
6.4%
3,507,695
SC 13G
Feb 14, 2023
nomura holdings inc
7.2%
2,952,334
SC 13G/A
Jul 08, 2022
blackrock inc.
1.6%
637,778
SC 13G
Feb 14, 2022
nomura holdings inc
5.3%
2,003,612
SC 13G
Feb 03, 2022
blackrock inc.
6.6%
2,500,721
SC 13G/A
Feb 11, 2021
elliott investment management l.p.
4.99%
7,136,979
SC 13D/A
Jan 29, 2021
blackrock inc.
6.2%
1,995,193
SC 13G/A
Aug 10, 2020
elliott investment management l.p.
5.8%
1,758,374
SC 13D

Recent SEC filings of CorMedix Inc

View All Filings
Date Filed Form Type Document
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 14, 2024
4
Insider Trading
Mar 12, 2024
8-K
Current Report
Mar 12, 2024
10-K
Annual Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to CorMedix Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

CorMedix Inc News

Latest updates
InvestorsObserver • 14 Mar 2024 • 03:00 pm
Yahoo Finance • 13 Mar 2024 • 07:00 am
Seeking Alpha • 12 Mar 2024 • 07:00 am
InvestorsObserver • 12 Mar 2024 • 07:00 am
Simply Wall St • 13 Feb 2024 • 08:00 am
Nasdaq • 3 months ago
The Motley Fool • 9 months ago
InvestorPlace • 9 months ago

CorMedix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue-100.0%-290,3106,81721,2537,63622,86238,0888,19188,26155,71493,02016,44374,05424,77859,53035,266163,69226,523372,5147,55023,210
Cost Of Revenue-100.0%-4061,4693321,52748,00725,16614,42661,33957,23279,91319,18448,51746,12579,02621,128226,95522,114312,43433,66328,575
Gross Profit-100.0%-29,2965,34820,9216,1098,39012,922-6,23526,922-1,51813,107-2,74125,537-21,347-19,49614,138-63,2634,40960,080-26,112-5,365
Operating Expenses86.1%15,668,7448,418,5246,967,2828,261,3667,038,4707,788,3108,577,8415,875,9937,237,4406,083,1226,616,8628,917,8685,637,2855,354,4775,152,0195,551,4944,859,918-2,133,82210,301,5338,546,03810,183,458
  S&GA Expenses140.0%13,379,8555,575,3024,628,0145,051,8954,750,8834,553,0913,836,6133,355,7904,601,1083,788,6933,691,5073,232,5763,165,1682,677,4702,631,0272,571,5871,984,9222,213,4402,012,4391,945,8251,903,016
  R&D Expenses-19.5%2,288,8892,843,2232,339,2683,209,4712,287,5873,235,2194,741,2282,520,2032,636,3322,294,4292,925,3555,685,2922,472,1172,677,0082,520,9922,979,9072,874,996-4,347,2618,289,0946,600,2138,280,442
EBITDA Margin0.0%-94.90-94.88-126-178-305-1,961-141-111-105-111-----------
Interest Expenses-25.3%6,5568,7768,7763,5855,3785,3785,381-5,1845,3227,80013,8286,2766,276172,429306,736302,048---1,873
Income Taxes-----585,617----1,250,186---3,138-5,169,3956,276---5,060,778-----
Earnings Before Taxes100.0%--8,208,951-6,853,721-8,190,456--7,790,987-8,569,366-5,883,121--6,086,945-6,600,747-8,951,819--5,304,185-5,264,847-5,756,936-5,412,604-10,236,119-8,556,911-
EBT Margin0%-95.22-95.22-126-178-306-1,966-142-112-106-112-----------
Net Income-79.3%-14,714,802-8,208,951-6,853,721-7,604,839-7,034,194-7,790,987-8,569,366-4,632,935-7,216,938-6,086,945-6,600,747-3,782,424-5,557,567-5,304,185-5,264,847-696,158-5,167,8842,148,518-10,236,119-8,556,911-10,185,118
Net Income Margin-55.9%-142-91.11-118-182-303-1,958-139-100-93.46-92.08-----------
Free Cashflow-75.7%-11,041,625-6,283,594-6,071,854-5,471,978-6,748,666-6,498,121-6,281,407-3,097,132-6,703,892-6,010,571-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-10.2%82.0091.0057.0059.0062.0062.0068.0065.0069.0075.0081.0084.0049.0040.0024.0027.0029.0034.0028.0027.0019.00
  Current Assets-10.8%79.0089.0055.0057.0060.0060.0065.0063.0066.0073.0080.0083.0048.0039.0024.0027.0029.0034.0027.0027.0019.00
    Cash Equivalents-17.8%44.0053.0020.0025.0043.0043.0049.0046.0054.0067.0073.0076.0042.0035.0017.0012.0017.0020.0015.0018.0018.00
  Inventory------269*0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
  Net PPE17.4%2.002.002.002.002.002.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities44.9%12.008.008.005.007.006.006.005.006.006.004.004.005.006.006.006.006.005.0011.0011.0014.00
  Current Liabilities48.6%11.008.007.005.006.005.005.004.005.005.003.003.004.005.006.006.006.005.004.004.008.00
Shareholder's Equity-15.7%70.0083.0049.0054.0055.0056.0062.0060.0063.0069.0077.0080.0044.0034.000.000.0024.0029.0016.0017.005.00
  Retained Earnings-4.8%-321-306-297-285-275-267-260-252-245-237-229-224-217-211-204-200-195-190-184-184-178
  Additional Paid-In Capital0.4%392390346340330323322312308307306305262246223222219219201201184
Shares Outstanding0.2%55.0055.0046.0044.0043.0040.0039.0038.0038.0038.0037.0036.0034.00--------
Float-------164---208---208---209--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-23.5%-10,745-8,697-8,572-10,393-6,154-5,995-5,462-6,744-5,869-5,503-3,091-6,690-5,933-7,312-754-7,966-3,884-3,964164-7,367-7,200
  Share Based Compensation21.4%1,2171,0031,0572,2168749841,0741,1381,2531,0481,0101,73251661169667745357160680919.00
Cashflow From Investing201.9%598-586-2,385-14,686-1.86-114594-4,187-7,129-1,271-208-526-1,8473,2435,045985296-477-3,874-7,964109*
Cashflow From Financing-98.9%46842,8995,3507,2006,0464378,4113,004--17741,58115,32221,943-2,835-20510,02914.0015,96818,384

CRMD Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:  
Net sales$ 65,408
Cost of sales(3,734)
Gross profit61,674
Operating Expenses:  
Research and development(13,155,125)(10,679,549)
Selling, general and administrative(35,802,663)(20,006,093)
Total operating expenses(48,957,788)(30,685,642)
Loss From Operations(48,957,788)(30,623,968)
Other Income (Expense):  
Interest income2,681,851326,016
Foreign exchange transaction (loss) income(28,994)37,145
Interest expense(34,296)(26,515)
Total other income2,618,561336,646
Net Loss Before Income Taxes(46,339,227)(30,287,322)
Tax benefit585,617
Net Loss(46,339,227)(29,701,705)
Other Comprehensive Income (Loss):  
Unrealized gain from investments9,6835,055
Foreign currency translation gain (loss)1,682(9,442)
Total other comprehensive gain (loss)11,365(4,387)
Comprehensive Loss$ (46,327,862)$ (29,706,092)
Net Loss Per Common Share – Basic (in Dollars per share)$ (0.91)$ (0.74)
Weighted Average Common Shares Outstanding – Basic (in Shares)50,902,93140,274,273

CRMD Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 43,642,684$ 43,148,323
Restricted cash77,453124,102
Short-term investments32,388,13015,644,062
Inventories, net2,106,345
Prepaid research and development expenses353,57411,016
Other prepaid expenses and current assets882,214623,672
Total current assets79,450,40059,551,175
Property and equipment, net1,866,2241,609,679
Restricted cash, long term103,055102,320
Operating lease right-of-use assets640,278775,085
TOTAL ASSETS82,059,95762,038,259
Current liabilities  
Accounts payable4,279,6792,202,149
Accrued expenses6,970,2173,973,941
Operating lease liabilities, short-term150,619134,801
Total current liabilities11,400,5156,310,891
Operating lease liabilities, net of current portion517,013667,632
TOTAL LIABILITIES11,917,5286,978,523
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS’ EQUITY  
Preferred stock - $0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at December 31, 2023 and 2022182182
Common stock - $0.001 par value: 160,000,000 shares authorized at December 31, 2023 and 2022; 54,938,258 and 42,815,196 shares issued and outstanding at December 31, 2023 and 2022, respectively54,93842,815
Accumulated other comprehensive gain94,10882,743
Additional paid-in capital391,693,214330,294,782
Accumulated deficit(321,700,013)(275,360,786)
TOTAL STOCKHOLDERS’ EQUITY70,142,42955,059,736
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 82,059,957$ 62,038,259
CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
 CEO
 WEBSITEwww.cormedix.com
 EMPLOYEES40

CorMedix Inc Frequently Asked Questions


What is the ticker symbol for CorMedix Inc? What does CRMD stand for in stocks?

CRMD is the stock ticker symbol of CorMedix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CorMedix Inc (CRMD)?

As of Wed Mar 27 2024, market cap of CorMedix Inc is 228.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers. The fair value of CorMedix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CorMedix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CorMedix Inc a good stock to buy?

The fair value guage provides a quick view whether CRMD is over valued or under valued. Whether CorMedix Inc is cheap or expensive depends on the assumptions which impact CorMedix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRMD.

What is CorMedix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, CRMD's PE ratio (Price to Earnings) is -4.94 and Price to Sales (PS) ratio is 576.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CorMedix Inc's stock?

In the past 10 years, CorMedix Inc has provided -0.111 (multiply by 100 for percentage) rate of return.